Alopecia is an autoimmune disorder that causes non-scarring hair loss on the scalp and body that is experienced by almost 2% ...
Researchers at the Center for Embryology and Healthy Development (CRESCO) aim to find out why so many early embryos fail in ...
Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
Bayer, Puhe BioPharma ink global license agreement for clinical phase I PRMT5 inhibitor: Berlin, Germany Friday, March 28, 2025, 13:00 Hrs [IST] Bayer and Suzhou Puhe BioPharma Co ...
CHO cells were the protein production platform used in 89% of the biologics drugs approved between 2018 and 2022, and their ...
Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors ...
NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback